Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORX489 in healthy adults
NCT07413666Phase 1Recruiting
- Sponsor
- Centessa Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ORX489 in narcolepsy, sponsored by Centessa Pharmaceuticals. Primary endpoint: Safety and Tolerability of ORX489. Started Feb 2026; status: recruiting.
02
Drugs
ORX489
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT07413666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413666.